Earnings ·
Protara reports $0.35 Q3 loss, buys manufacturing assets for $8.75M
PRTOProtara Therapeutics, Inc.
Protara Therapeutics reported a net loss of $21.7 million, or $0.35 per share, for the third quarter ended September 30, 2026, compared to a $13.3 million loss in the prior-year period. Research and development expenses rose to $16.8 million from $9.6 million, driven by higher clinical trial costs and personnel-related expenses. The company holds approximately $143 million in cash and investments, sufficient to fund operations into 2028. Additionally, Protara entered an asset purchase agreement with Novex Innovations for TARA-002 manufacturing assets for $8.75 million to bring production capabilities in-house. Protara is a clinical-stage biotechnology company developing therapies for cancer and rare diseases.